Alector reports fourth quarter and full year 2023 financial results and provides business update

Data from invoke-2, evaluating the most advanced trem2 candidate in clinical development for early alzheimer's disease (ad), expected in q4 2024; trial enrollment completed in q3 2023

ALEC Ratings Summary

ALEC Quant Ranking